Erythropoietin Therapy

Anaemia is one of the more common complications of CKD, and it’s a major reason cats with the disease can feel run down, weak, or lethargic beyond what their bloodwork numbers alone might suggest. For mild cases, there are simple, low-cost treatments. For more severe anaemia, a category of medication called erythropoiesis stimulating agents (ESAs) can be genuinely life-extending, though the decision to start one is not a small one. This post focuses mainly on ESA therapy, since that’s the part that tends to generate the most questions and the most hesitation from vets.

Healthy kidneys produce a hormone called erythropoietin, which tells the bone marrow to keep making red blood cells. As CKD damages the kidneys, erythropoietin production drops, the bone marrow slows down, and a type of anaemia called non-regenerative anaemia develops. This is the most common cause of anaemia in CKD cats, though uraemic toxins and other CKD-related issues can also play a role.

Anaemia on its own isn’t necessarily a poor prognostic sign. Many cats live for months or longer even with meaningfully anaemic bloodwork. But when it’s severe, or when it’s causing obvious symptoms, it becomes worth addressing directly rather than working around.

For cats with milder anaemia, before jumping to an ESA, a few simpler steps are usually tried first:

• B vitamins, particularly B12, since deficiencies can worsen or contribute to non-regenerative anaemia
• Iron supplementation, since iron deficiency is common in CKD cats and can blunt the effectiveness of red blood cell production even before an ESA is involved
• Addressing any other contributing issues, like inflammation or infection, which can suppress red blood cell production independently of CKD

These steps matter even for cats who do eventually need an ESA, since iron and B vitamins are the “building blocks” that let an ESA actually do its job.

Erythropoiesis stimulating agents are forms of erythropoietin (mostly human formulations, since a commercially available feline version doesn’t currently exist) that step in to stimulate the bone marrow directly. They’re not a first-line treatment, but for a cat with genuinely severe anaemia, they’re often the only thing standing between the cat and a slow decline from anaemia itself, separate from the kidney disease.

General signals that it’s time to have this conversation with your vet:

• PCV or HCT persistently below 20%, especially if it developed gradually rather than suddenly
• Symptoms of anaemia are present and affecting quality of life: lethargy, breathlessness, poor appetite
• The anaemia is confirmed or strongly suspected to be non-regenerative and caused by a lack of erythropoietin, which is more likely in cats with more advanced CKD

A sudden, sharp drop in PCV (rather than a gradual decline) is a red flag for something else going on, like gastrointestinal bleeding, and should prompt investigation rather than an automatic move to an ESA.

There are two categories of human erythropoietin used in cats, since a feline-specific version isn’t commercially available.

Darbepoetin alfa (Aranesp) is now generally considered the best choice for most cats. It’s structurally different enough from the older products that it appears significantly less likely to trigger the antibody reaction described below, cited at around a 10% rate compared to considerably higher rates for the older products. The tradeoffs are a higher upfront cost per vial and a potentially slower onset of effect for some cats, though it’s given less frequently, which evens out the cost somewhat over time.

Epoetin alfa (Epogen, Procrit, or Eprex depending on your country) tends to act faster and costs less upfront, which can make it the practical choice for a cat in more urgent need, or as a bridge before switching to darbepoetin. Its main downside is a meaningfully higher rate of the antibody reaction with longer-term use.

Epoetin beta (NeoRecormon) is a less commonly used option, mainly available outside the US, with similar general principles to epoetin alfa.

If starting cost or a genuinely urgent need makes epoetin alfa the more practical choice initially, it’s entirely possible to switch to darbepoetin later using a dosage conversion your vet can calculate.

Dosing is based on your cat’s weight and varies by product, with several published protocols to choose from. This is very much a “work closely with your vet” situation rather than something to calculate on your own, since getting the dose wrong in either direction has real consequences. Too little and the anaemia won’t resolve; too much, or too fast a rise in PCV, increases the risk of hypertension and related complications.

A few general principles apply across all the ESAs:

• Always check PCV before giving the next dose, not just on a fixed schedule, in case your cat is responding faster than expected
• A rise of around 2% per week in PCV is the general target; faster rises should prompt a conversation with your vet about reducing the dose
• Blood pressure needs monitoring throughout, since 40 to 50% of cats on ESAs develop hypertension
• Iron and B vitamin supplementation should continue throughout treatment as the “building blocks” that let the ESA work

Expect PCV to start rising within one to three weeks, with the target range typically reached within three to twelve weeks depending on how severe the anaemia was to start. Once target PCV is reached, the dose and frequency are usually reduced to a maintenance level rather than stopped, since anaemia typically returns if the ESA is discontinued.

This is the main reason some vets are hesitant to prescribe ESAs, and it’s worth understanding clearly rather than being frightened by. Because these medications are human proteins, a cat’s immune system can eventually recognise them as foreign and produce antibodies against them. This neutralises the ESA’s effect, and in its most severe form, called pure red cell aplasia (PRCA), the antibodies can also attack the cat’s own existing red blood cell production.

A few things are worth knowing:

• It typically doesn’t happen in the first month of treatment, and if it’s going to happen, it’s usually around four to five months in
• Rates cited in the literature vary widely (from around 10% for darbepoetin up to much higher historical estimates for epoetin alfa based on older, higher-dose studies), and real-world experience among long-term CKD caregiver communities generally suggests lower rates than the most-cited studies imply
• Not every cat who develops antibodies loses all benefit from the ESA. In milder cases, the ESA may keep working despite antibodies being present
• If it does happen, the only remedy is stopping the ESA and managing anaemia through other means (potentially blood transfusions) until antibodies clear, which can take months

Before assuming the antibody reaction is the cause of a falling or plateaued PCV, other more common and treatable causes should be ruled out first: dehydration affecting the reading, insufficient iron, infection or inflammation, an incorrect dose, or a degraded/improperly stored vial.

This is genuinely one of the harder calls in CKD management, and there’s no universally right answer. What tends to help caregivers reach a decision they feel good about:

• Recognising that untreated severe anaemia will itself shorten a cat’s life and reduce quality of life, so “doing nothing” isn’t actually the neutral or safe option it might feel like
• Understanding that even in a worst-case scenario where the antibody reaction develops, an ESA will typically have bought several months of improved quality of life before that happens
• Knowing that darbepoetin’s lower antibody risk makes it a reasonable default starting point for most cats, cost permitting

Is anaemia dangerous on its own, separate from CKD? Yes. Even though many cats tolerate mild to moderate anaemia reasonably well, severe anaemia reduces oxygen delivery throughout the body and can itself become life-limiting, independent of how well the underlying CKD is otherwise managed.

What’s the difference between darbepoetin and epoetin alfa? Darbepoetin is generally considered lower risk for the antibody reaction and is given less frequently, but costs more upfront and may act more slowly. Epoetin alfa is cheaper per dose and tends to act faster, but carries a higher long-term risk of the antibody reaction.

How do I give an ESA at home? These are given by subcutaneous injection, the same general technique used for sub-Q fluids. Your vet can walk you through dosing and injection technique, and most caregivers do end up giving these at home rather than at the clinic.

What if my cat’s PCV isn’t rising on an ESA? Don’t panic and don’t assume it’s the antibody reaction right away. Check for dehydration at the time of testing, confirm iron and B vitamin supplementation are in place, and rule out infection, inflammation, or an issue with the dose or the vial itself. Most non-response has a more common, fixable cause.

Can I stop and restart an ESA to save money or reduce the antibody risk? This isn’t recommended. Stopping and restarting doesn’t appear to reduce antibody risk and may actually increase it, and it allows anaemia to return in the meantime, which isn’t good for your cat’s quality of life or your ability to manage fluctuating PCV levels.

Does every cat on an ESA develop hypertension? No, but it’s common enough (40 to 50% in the cited literature) that blood pressure monitoring should be part of your routine for as long as your cat is on an ESA, especially early in treatment.

• Cowgill LD, James KM, Levy JK, Egrie JC, Browne JK, Miller A, Lobinger R. “Use of Recombinant Human Erythropoietin for Management of Anaemia in Dogs and Cats with Renal Failure.” Journal of the American Veterinary Medical Association 212, 1998, pp. 521-528.
• Chalhoub S, Langston C, Eatroff A. “Anaemia of Renal Disease: What Is It, What to Do and What’s New.” Journal of Feline Medicine and Surgery 13(9), 2011, pp. 629-640.
• Chalhoub S, Langston C, Farrelly J. “The Use of Darbepoetin to Stimulate Erythropoiesis in Anemia of Chronic Kidney Disease in Cats: 25 Cases.” Journal of Veterinary Internal Medicine 23(2), 2012, pp. 363-369.
• Chalhoub S, Langston CE. “Managing Anemia in Patients with Chronic Kidney Disease.” Veterinary Medicine, May 2011.
• Langston CL. “Anemia of Chronic Kidney Disease.” CVC in San Diego Proceedings, 2009.
• Sparkes AH, Caney S, Chalhoub S, Elliott J, Finch N, Gajanayake I, Langston C, Lefebvre H, White J, Quimby J. “ISFM Consensus Guidelines on the Diagnosis and Management of Feline Chronic Kidney Disease.” Journal of Feline Medicine and Surgery 18, 2016, pp. 219-239.
• Gest J, Langston C, Eatroff A. “Iron Status of Cats with Chronic Kidney Disease.” Journal of Veterinary Internal Medicine 29, 2015, pp. 1488-1493.
• Rossert J, Fouqueray B, Boffa JJ. “Anemia Management and the Delay of Chronic Renal Failure Progression.” Journal of the American Society of Nephrology 14, 2003, pp. 173-177.
• Polzin DJ. “Evidence-Based Step-Wise Approach to Managing Chronic Kidney Disease in Dogs and Cats.” Journal of Veterinary Emergency and Critical Care 23(2), 2013, pp. 205-215.
• Schellekens H, Jiskoot W. “Erythropoietin-Associated PRCA: Still an Unsolved Mystery.” Journal of Immunotoxicology 3(3), 2006, pp. 123-130.